Adherence to Pediatric Universal Cholesterol Testing Guidelines Across Body Mass Index Categories: A CER Cohort Study.

TitleAdherence to Pediatric Universal Cholesterol Testing Guidelines Across Body Mass Index Categories: A CER Cohort Study.
Publication TypeJournal Article
Year of Publication2020
AuthorsGregory EF, Miller JM, Wasserman RC, Seshadri R, Grundmeier RW, Rubin DM, Fiks AG
JournalCirc Cardiovasc Qual Outcomes
PaginationCIRCOUTCOMES119006519
Date Published2020 Jul 17
ISSN1941-7705
Abstract

In 2011, the American Academy of Pediatrics (AAP) and NHLBI recommended universal cholesterol testing at age 9 to 11 years, discussing 2 rationales. The first rationale was identification of familial hypercholesterolemia, a severe disease with a prevalence of ≈ 1:300. The long-term safety and benefits of cholesteral-lowering medications for youth with severe hypercholesterolemia have been established. These known benefits increase the value of early disease identification. The second rationale was identification of less severe dyslipidemias associated with pediatric obesity that may represent a modifiable risk for cardiovascular disease. Before 2011, pediatric cholesterol testing was most common among children with known cardiovascular risks, particularly obesity. Questions remain about the role of universal testing in pediatrics, and the United States Preventive Services Task Force has not endorsed universal testing. This uncertainty may influence guideline uptake.

Prior reports examining cholesterol testing in pediatric cohorts predate the 2011 guideline, evaluate specific efforts to adopt the guideline, or were unable to evaluate other cardiovascular risk factors that may be associated with testing. This study asks whether, and to what extent, universal testing has been adopted since the 2011 guideline.

DOI10.1161/CIRCOUTCOMES.119.006519
Alternate JournalCirc Cardiovasc Qual Outcomes
PubMed ID32674639